US OptionsDetailed Quotes
WGS241220P57500
- 0.75
- -0.92-55.09%
15min DelayClose Nov 22 15:54 ET
0.75High0.60Low
0.60Open1.67Pre Close2 Volume55 Open Interest57.50Strike Price135.00Turnover89.37%IV27.90%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.75Extrinsic Value100Contract SizeAmericanOptions Type-0.0780Delta0.0076Gamma104.95Leverage Ratio-0.0503Theta-0.0047Rho-8.18Eff Leverage0.0314Vega
GeneDx Holdings Stock Discussion
Sign in to post a comment
been holding these shares $GeneDx Holdings (WGS.US)$ for about 2 months now on a different investing app, original plan was to sell at 65 but after a sudden 44% jump, im rethinking if i should hold longer or sell. something tells me to walk away while im up, but it also seems like it could go higher. or should I sell now and buy again after a big dip? any thoughts and openions would be greatly appreciated.
1
$Fundamental Global (FGF.US)$ $Canaan (CAN.US)$ $NovaBay Pharmaceuticals (NBY.US)$ $Icecure Medical (ICCM.US)$ $Upexi (UPXI.US)$ $Shuttle Pharmaceuticals (SHPH.US)$ $Innovative Eyewear (LUCY.US)$ $Lightbridge (LTBR.US)$ $GeneDx Holdings (WGS.US)$ $Profire Energy (PFIE.US)$ $Lixte Biotechnology (LIXT.US)$ $J-Long Group (JL.US)$ $BIO-key International (BKYI.US)$ $GlycoMimetics (GLYC.US)$
3
1
$GeneDx Holdings (WGS.US)$
The risk level for GeneDx Holdings Corp. is high due to multiple factors that elevate volatility and potential drawdowns. The company's inability to maintain profitability and high debt levels relative to cash position are concerning for long-term financial stability. GeneDx's impressive short-term stock surge, while promising, rests heavily on recent positive news, making the price susceptible to sudden reversals if sentiments shift. Moreover, the stock's failure to e...
The risk level for GeneDx Holdings Corp. is high due to multiple factors that elevate volatility and potential drawdowns. The company's inability to maintain profitability and high debt levels relative to cash position are concerning for long-term financial stability. GeneDx's impressive short-term stock surge, while promising, rests heavily on recent positive news, making the price susceptible to sudden reversals if sentiments shift. Moreover, the stock's failure to e...
4
Hello Mooers! ![]()
A quick recap for the month ending April 30, 2024.
![]()
Ten stocks with >300% YTD
![]()
$Swvl Holdings (SWVL.US)$718.40%
![]()
$Root Inc (ROOT.US)$564.60%
![]()
$Elevation Oncology (ELEV.US)$561.08%
![]()
$JanOne (JAN.US)$554.05%
![]()
$GeneDx Holdings (WGS.US)$520.71%
![]()
$Corbus Pharmaceuticals (CRBP.US)$513.25%
![]()
$AGBA Group (AGBA.US)$482.90%
![]()
$Janux Therapeutics (JANX.US)$431.22%
![]()
$Dave Inc (DAVE.US)$4...
A quick recap for the month ending April 30, 2024.
4
1
$GeneDx Holdings (WGS.US)$
NEWS
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
NEWS
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
1
The low P/S of GeneDx Holdings indicates investors expect limited future growth. A recent share price boost hasn't shifted investor perceptions. The low P/S is largely because shareholders are pessimistic about revenue prospects.
No comment yet
Bigmoney Dreamer : ALWAYS KNOW YOUR RISK TOLERANCE
The risk level for GeneDx Holdings Corp. is high due to multiple factors that elevate volatility and potential drawdowns. The company's inability to maintain profitability and high debt levels relative to cash position are concerning for long-term financial stability. GeneDx's impressive short-term stock surge, while promising, rests heavily on recent positive news, making the price susceptible to sudden reversals if sentiments shift. Moreover, the stock's failure to establish clear support after the recent high suggests a fragile price structure, increasing the likelihood of a sharp downturn if market conditions worsen. The absence of sector-level support further heightens risk, positioning the stock as a highly speculative trade.